Cargando…

Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study

Non-muscle-invasive bladder cancer (NMIBC) is categorized into high-risk and low-risk groups. Although, bacillus Calmette-Guerin (BCG) is the recommended adjuvant therapy of high-risk bladder tumor, optimal schedule (induction versus maintenance) of this therapy is a subject of debate. The objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirzada, Muhammad T, Ghauri, Rashid, Ahmed, Monis J, Shah, Muhammad F, Nasir, Irfan ul Islam, Siddiqui, Jasim, Ahmed, Irfan, Mir, Khurram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Urology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291702/ https://www.ncbi.nlm.nih.gov/pubmed/28168135 http://dx.doi.org/10.7759/cureus.957

Ejemplares similares

Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience
por: Ali, Azfar, et al.
Publicado: (2019)

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)
por: Witjes, J Alfred, et al.
Publicado: (2013)

The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article
por: Kodera, Ahmed, et al.
Publicado: (2023)

Rectal Carcinoma: Demographics and Clinicopathological Features from Pakistani Population Perspective
por: Pirzada, Muhammad T, et al.
Publicado: (2017)

Outcomes of Uretero-ileal Anastomosis in Bladder Cancer Cystectomies: Bricker vs. Wallace 1
por: Adnan, Siddique, et al.
Publicado: (2022)

Comparison of Outcomes Between Radical Radiotherapy and Radical Cystectomy in Muscle Invasive Bladder Cancer in a Cancer Specialized Unit of a Developing Country
por: Fiaz, Shaukat, et al.
Publicado: (2020)

Oncological Outcomes of Non-Urothelial Bladder Cancers in a Specialized Cancer Hospital of a Developing Country
por: Adnan, Siddique, et al.
Publicado: (2020)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review
por: He, Yuhui, et al.
Publicado: (2018)

Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy
por: Afonso, Raquel, et al.
Publicado: (2022)

Outcomes of Nephron Sparing in a Specialist Cancer Hospital of a Developing Country
por: Khalil, Muhammad Arshad Irshad, et al.
Publicado: (2019)

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG
por: Kashif Khan, Muhammad, et al.
Publicado: (2014)

Candida Bezoar of the Bladder Resulting in Obstructive Uropathy: A Case Report
por: McGhee, Nicholas M, et al.
Publicado: (2023)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2022)

Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol
por: Bieri, Uwe, et al.
Publicado: (2022)

A Self Inserted Unusual Foreign Body “An Entire Pencil” in a Male Urethra and Bladder: A Case Report
por: Ahmed, Mohammed M, et al.
Publicado: (2022)

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
por: Cooper, Owen Alan Edwards, et al.
Publicado: (2023)

Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis
por: Hinduja, Sanjay, et al.
Publicado: (2020)

Bladder Embryonal Rhabdomyosarcoma Among Children: A Descriptive Overview From Saudi Arabia
por: Alghafees, Mohammad A, et al.
Publicado: (2022)

Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer
por: Bieri, Uwe, et al.
Publicado: (2023)

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review
por: Yeowell, Gillian, et al.
Publicado: (2018)

BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants
por: Suh, Jungyo, et al.
Publicado: (2019)

Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC)
por: Farah, Naim B, et al.
Publicado: (2014)

Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
por: Broughton, Edward I., et al.
Publicado: (2022)

Long-term Follow-up of Exstrophy-epispadias Complex from a Lower-middle Income Country: A Case Report and Review of the Literature
por: Irfan, Omar, et al.
Publicado: (2020)

Primary Carcinoma In Situ of the Ureter Without Concurrent Renal Pelvis or Bladder Carcinoma: A Case Report and Literature Review
por: Farah, Mohamed, et al.
Publicado: (2023)

Congenital bladder diverticulum with benign bladder wall lesion resembling rhabdomyosarcoma
por: Mak, David K-C, et al.
Publicado: (2010)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)
por: Häggström, Christel, et al.
Publicado: (2017)

Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG)
por: Steinberg, Gary, et al.
Publicado: (2015)

A Prospective Evaluation of the Association of Ureteral Wall Thickness With Intraoperative Stone Impaction in Ureteroscopy
por: Rasheed, Yasir, et al.
Publicado: (2023)

Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0
por: Häggström, Christel, et al.
Publicado: (2022)

Painful Ejaculation - An Ignored Symptom
por: Waqar, Muhammad, et al.
Publicado: (2020)

Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
por: Busetto, Gian Maria, et al.
Publicado: (2023)

Comparison of the Efficacy of Tramadol and Paroxetine in the Management of Premature Ejaculation
por: Ur Rehman, Muhammad Fazal, et al.
Publicado: (2020)

Idiopathic Pneumatosis of Small Bowel and Bladder
por: Gupta, Anupam K, et al.
Publicado: (2020)

A Rare Case of Bladder Perineurioma
por: Ferraz de Arruda, Germano José, et al.
Publicado: (2022)

Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study
por: Jamil, Marcus L, et al.
Publicado: (2019)

High-Grade Non-Muscle Invasive Bladder Cancer: When to Move to Early Radical Cystectomy?
por: Azhar, Raed A, et al.
Publicado: (2021)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4mh6s5kkc77dleif6jp5lhvrk8